drugset / Trial / NCT04477096

Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine

NCT04477096

Phase 1 Completed 36 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
NaSequentialOpen-labelOther

Summary

The study is being conducted to evaluate drug interaction between HS-10234 and Emtricitabine after multiple dose in healthy subjects.

Timeline

Start
2020-08-03
Primary completion
2020-09-24
Completion
2020-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10234 Unknown 25 mg Oral
Subject emtricitabine Other / unclassified 200 mg Oral

Indications

No indication recorded.